Program
GSK5926371
A development code.
In GlaxoSmithKline's pipeline, Anti CD19-CD20-CD3 trispecific antibody
. Its studies are mostly in Lymphoma, Non-Hodgkin · Lupus Erythematosus, Systemic, led by GlaxoSmithKline.
Furthest: phase 2, since May 19, 20262 company-led studies, 2 open or runningNext primary completion: Mar 15, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 22 open or running | phase 2since May 19, 2026 | Jan 19, 2026 | Mar 15, 2028phase 1 · NCT07371468 |
- Named in GlaxoSmithKline’s own pipeline as
GSK5926371
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 19, 2026First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT07371468 · 44 planned · Argentina, Brazil, France and more
- May 19, 2026Phase 2 study in Lymphoma, Non-HodgkinPhase 2 reachedNCT07607925 · 49 planned · United States, Australia, Canada and more
- Oct 30, 2026Primary completion moved from 2029-09-24 to 2030-01-10Date moved laterphase 2 · +4 months · NCT07607925
Ahead
- Mar 15, 2028Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07371468
- Jan 10, 2030Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07607925
TargetBeta
“Anti CD19-CD20-CD3 trispecific antibody”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07607925Lymphoma, Non-Hodgkin · United States, Australia, Canada and more | 2 | Recruiting | Jan 10, 2030 | 49 |
| NCT07371468Lupus Erythematosus, Systemic · Argentina, Brazil, France and more | 1 | Recruiting | Mar 15, 2028 | 44 |
How it is read
Names in the registry
- “GSK5926371”, 2 entries
Codes read as this program: GSK5926371.
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.